You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Indication

Nucala is available in a pre-filled pen¹.

Indication

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult, adolescents and children aged 6 years and older. 1

The recommended dose of Nucala is 100mcg SC once every 4 weeks in adults and adolescents 12 years and older, available in pre-filled pen, pre-filled syringe or as a lyophilised powder.

The licence dose of Nucala in children aged 6-11 years is 40mg SC once every 4 weeks regardless of weight, and is available as a lyophilised powder. 1

The pre-filled formulations are not indicated in 6-11 year olds.

Nucala is administered as a single injection, once every 4 weeks. Patients may need to plan for about 13 injections every year. 1

NUCALA is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. 1

ELIGIBILITY CRITERIA AS DEFINED BY THE HSE

Please refer to the HSE's protocol on use of Mepolizumab for the treatment of severe refractory eosinophilic asthma

  • Diagnosed with severe refractory eosinophilic asthma by a Specialist Respiratory Physician
  • Adherence to Maintenance Therapy confirmed
  • Patient’s inhaler technique has been assessed and the patient has been educated on inhaler use.
  • Patient’s compliance with prescribed therapy has been assessed at 3 consecutive monthly visits to CNS, has received adherence advice, PEFR diary and reported asthma outcomes have been assessed or ideally using an adherence measuring device over 3 months. 2
and meets the below criteria:
Indication

OCS; oral corticosteroids
CNS; Clinical Nurse Specialist
PEFR; Peak Expiratory Flow Rate

What is Nucala?

Nucala is a humanised monoclonal antibody that:

  • Blocks the binding of IL-5 to the eosinophil cell surface 1
  • Inhibits IL-5 signalling and the growth, activation and survival of eosinophils 3
  • Significantly reduces blood eosinophil levels 1 4
What is Nucala

Nucala Mode of Action

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/Ireland/MP4/mode-of-action-video-mepo-moa-commercial.mp4

Watch a visual exploration of Nucala (mepolizumab) and its structure-function relationship.

ED, emergency department; OCS, oral corticosteroids

† Standard of care - High dose ICS and additional maintenance treatment(s)

References:

  1. Nucala summary of Product Characteristics. Available at  www.medicines.ie. Last Accessed November 2020.
  2. HSE's Mepolizumab (Nucala) Protocol for the treatment of severe refractory eosinophilic asthma, available on www.hse.ie, accessed November 2020.
  3. Garcia G et al. Eur Respir Rev 2013; 22:251-257.
  4. Ortega HG et al. Eur Respir J 2014; 44:239-241.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

NUCALA is a registered trademark of the GlaxoSmithKline Group of Companies.